Your browser is no longer supported. Please, upgrade your browser.
Settings
GNPX Genprex, Inc. daily Stock Chart
GNPX [NASD]
Genprex, Inc.
Index- P/E- EPS (ttm)-0.88 Insider Own5.30% Shs Outstand15.94M Perf Week-1.11%
Market Cap28.37M Forward P/E- EPS next Y-0.87 Insider Trans- Shs Float7.50M Perf Month-1.39%
Income-12.40M PEG- EPS next Q-0.20 Inst Own14.40% Short Float1.36% Perf Quarter13.38%
Sales- P/S- EPS this Y-253.40% Inst Trans- Short Ratio2.10 Perf Half Y27.14%
Book/sh0.59 P/B3.02 EPS next Y-8.70% ROA-143.10% Target Price4.25 Perf Year-84.89%
Cash/sh0.54 P/C3.30 EPS next 5Y- ROE-155.10% 52W Range0.95 - 12.67 Perf YTD61.82%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-85.95% Beta-
Dividend %- Quick Ratio22.80 Sales past 5Y- Gross Margin- 52W Low87.37% ATR0.10
Employees4 Current Ratio22.80 Sales Q/Q- Oper. Margin- RSI (14)48.80 Volatility5.18% 5.23%
OptionableNo Debt/Eq0.01 EPS Q/Q-343.90% Profit Margin- Rel Volume0.73 Prev Close1.78
ShortableYes LT Debt/Eq0.00 EarningsMar 26 Payout- Avg Volume48.61K Price1.78
Recom2.00 SMA20-0.12% SMA500.82% SMA200-1.29% Volume35,680 Change0.00%
Apr-29-19Initiated Noble Capital Markets Outperform $5
May-09-19 08:30AM  Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Promising New Gene Therapies GlobeNewswire
May-08-19 08:30AM  Genprex Retains Addison Whitney for Drug Nomenclature Branding Business Wire
08:30AM  Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Gene Therapies for Cancer Treatment GlobeNewswire
Apr-12-19 09:00AM  Genprex Featured in NetworkNewsAudio Broadcast on Potential Gene Therapy Treatment for Cancer Newsfile
09:00AM  Genprex (GNPX) Featured in NetworkNewsAudio Broadcast Discussing Gene Therapy Programs on the Cusp of Curing the Incurable GlobeNewswire
Apr-11-19 08:30AM  Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Cancer and Gene Therapy Treatment GlobeNewswire
08:30AM  Genprex (GNPX) Featured in NetworkNewsWire Publication about Revolutionary Gene Therapies Newsfile
Apr-08-19 08:30AM  Genprex Collaborators Report Positive TUSC2 and Checkpoint Blockade Preclinical Data at the 2019 AACR Annual Meeting Business Wire
Apr-01-19 08:30AM  Genprex Provides Clinical, Corporate, and Financial Update for the Year Ending December 31, 2018 Business Wire +5.79%
Mar-29-19 09:00AM  Genprex Featured in NetworkNewsAudio Publication on Unprecedented Targeting in Cancer Treatment Newsfile -6.23%
09:00AM  Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Advanced Medical Cancer Therapy GlobeNewswire
Mar-28-19 08:30AM  Genprex Featured in NetworkNewsWire Publication on Innovations in Cancer Therapy Newsfile
08:30AM  Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Innovative Cancer Treatments GlobeNewswire
Mar-19-19 08:30AM  Genprex Inc. Discusses Plans to Expand Clinical Trials in Fight Against Cancer in Exclusive Audio Interview with NetworkNewsWire GlobeNewswire
Mar-15-19 09:00AM  NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.'s Transformative Work in Gene Therapy Newsfile
08:30AM  NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.s Innovative Approach to Gene Therapy GlobeNewswire
Mar-14-19 08:30AM  NetworkNewsWire Announces Publication on Gene Therapys Promise for Improving Patient Treatments and Market Profitability GlobeNewswire +36.08%
08:30AM  Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City Business Wire
Mar-13-19 05:31PM  5 Biotech Stocks to Keep an Eye on in 2019 GuruFocus.com +5.33%
Feb-27-19 08:30AM  Genprex Strengthens Senior Team and Continues to Advance Operations Business Wire
Feb-19-19 08:30AM  Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors Business Wire -5.27%
Jan-23-19 08:30AM  Genprex to Present at NobleConXV in Fort Lauderdale, Florida Business Wire
Jan-03-19 08:30AM  Genprex to Present at Biotech Showcase 2019 in San Francisco Business Wire -8.58%
Dec-25-18 01:14PM  Are Insiders Buying Genprex, Inc. (NASDAQ:GNPX) Stock? Simply Wall St.
Dec-12-18 08:30AM  Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019 Business Wire
Dec-03-18 08:30AM  Genprex to Present at the 11th Annual LD Micro Main Event Business Wire -8.55%
Nov-20-18 08:30AM  Genprex Provides Clinical and Corporate Update for Third Quarter 2018 Business Wire
Oct-30-18 08:00AM  Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations Business Wire +8.54%
Oct-01-18 08:00AM  Genprex to Present at Upcoming Investor and Industry Conferences Business Wire -5.29%
Sep-27-18 08:00AM  Genprex Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program Business Wire
Aug-21-18 08:30AM  Genprex to Present at Upcoming Investor Conferences Business Wire
Aug-15-18 08:30AM  Genprex Provides Clinical and Corporate Update for Second Quarter 2018 Business Wire
Aug-02-18 08:30AM  Genprex Updates Agreement with University of Texas MD Anderson Cancer Center to Resume Patient Enrollment in Phase I/II Study Evaluating Oncoprex/Erlotinib Combination Therapy in Non-Small Cell Lung Cancer Business Wire
Jul-26-18 08:30AM  Genprex Enters Agreement with the University of Texas MD Anderson Cancer Center to Study Oncoprex in Combination with Immunotherapies Business Wire
Jul-18-18 04:17PM  Genprex To Present At The Singular Research Summer Solstice 2018 Conference PR Newswire
Jul-02-18 09:30AM  Diamond Equity Research Initiates Coverage on Genprex Inc. (NASDAQ: GNPX) with a Valuation of $13 Per Share GlobeNewswire
Jun-26-18 08:00AM  Genprex Selects 4Clinics To Provide Clinical And Regulatory Support For Oncoprex Development Program PR Newswire +11.46%
May-31-18 08:30AM  Genprex Engages WIRB-Copernicus Group, Inc. To Provide Clinical Trial Services To Support Oncoprex Clinical Trial Program PR Newswire +10.30%
May-29-18 08:30AM  Genprex (Nasdaq: GNPX) To Ring The Nasdaq Stock Market Closing Bell PR Newswire
May-23-18 10:55AM  Genprex To Present At Upcoming Investor And Industry Conferences PR Newswire
May-08-18 08:00AM  Genprex Selects Accenture To Support Acceleration Of Oncoprex Clinical Development Program PR Newswire +15.22%
May-07-18 08:05AM  Genprex To Present At 2018 Disruptive Growth & Healthcare Conference PR Newswire
08:00AM  Genprex Announces $10 Million Private Placement PR Newswire
Apr-27-18 08:20AM  Todays Research Reports on Stocks to Watch: Genprex and Celgene ACCESSWIRE +38.27%
Apr-26-18 08:05AM  Genprex, New IPO in Biotech Generates Investor Interest with Lung Cancer Program ACCESSWIRE +86.76%
Apr-25-18 08:00AM  Genprex Expands Operations to Cambridge, Mass ACCESSWIRE +18.28%
Apr-18-18 09:00AM  Genprex Joins The Health Discovery Building At Dell Medical School To Help Drive Innovation For Health And Life Sciences PR Newswire
Apr-16-18 09:00AM  Genprex Provides Clinical and Corporate Update PR Newswire -5.46%
Apr-11-18 09:00AM  Genprex Appoints Julien Pham, MD, MPH As President To Lead Commercialization Of Oncoprex Immunogene Therapy PR Newswire +7.84%
Apr-10-18 08:35AM  Genprex (GNPX) Stock: May Offer Significant Growth Opportunity ACCESSWIRE -6.53%
Apr-04-18 08:30AM  Genprex Announces Closing of Initial Public Offering PR Newswire -6.34%
Mar-29-18 08:30AM  Genprex Announces Pricing of Initial Public Offering of Common Stock PR Newswire
Genprex, Inc. operates as a clinical stage gene therapy company. It is involved in developing various approaches to treating cancer, based upon a proprietary technology platform, including Oncoprex immunogene therapy for non-small cell lung cancer. Oncoprex that has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells and re-establishes pathways for apoptosis, or programmed cell death in cancer cells; and modulates the immune response against cancer cells, as well as blocks mechanisms that create drug resistance. The company was founded in 2009 and is headquartered in Austin, Texas.